Current Clinical Trials

Clinical Trials

Study Title Minimum Age Maximum age Who Can Join? Phase Status
Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate (BIA-2093-213)

Epilepsy, stroke

30 80 All 2 Recruitment terminated
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene (BIA-28-6156-201)

Parkinson Disease, GBA1 gene, Pathogenic variant

NCT05819359

35 80 All 2 recruiting
A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label Extension (BIA-91067-303)

Early Parkinson Disease

NCT04978597

30 80 All 3 Recruitment terminated
A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson’s Disease (BIA-91067-403)

Parkinson Disease, Motor fluctuations

NCT04990284

30 n.a. All 4 Recruitment terminated
Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with end-of-dose motor fluctuations and associated pain (BIA-91067-404)

Parkinson Disease, Motor fluctuations, Pain

NCT04986982

30 n.a. All 4 Recruiting
Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders (BIA-91067-405)

Parkinson Disease, Motor fluctuations, Sleep Disorders

NCT04986995

30 n.a. All 4 Recruitment terminated